AMA Guides Digital Cedaron
Home
AMA Guides Editions ▾
  • 6th Edition 2025
  • 6th Edition 2024
  • 6th Edition 2023
  • 6th Edition 2022
  • 6th Edition 2021
  • 6th Edition 2008
  • 5th Edition
  • 4th Edition
  • 3rd Edition Revised
AMA Guides Newsletters Search Case Scenarios Subscribe Log In

AMA Guides® Newsletter - Issue Archive

Volume 11 (2006): Issue 3 (May) < Previous Issue Next Issue >

Articles

  1. Erroneous Impairment Ratings

    Christopher R. Brigham

    Pages 1–5, 9-11

    DOI: 10.1001/amaguidesnewsletters.2006.MayJun01

    Abstract
    A nationwide study in 2005 of 2100 cases referred for impairment rating review found 80% to be erroneous, and 89% of these erroneous ratings were higher than appropriate. Among whole person erroneous ratings (839 of 1037 cases critiqued), the original physician's rating averaged 15.5% whole person permanent impairment, but following rerating by physician experts, the corrected rating averaged 5.6%; only 7% of the cases were underrated. All ratings were based on the AMA Guides to the Evaluation of Permanent Impairment, (AMA Guides), Fifth Edition. Tables and figures show error rates according to portion of the body affected, expert vs original rating, and other explanatory variables. Two physicians who use the AMA Guides should arrive at similar conclusions about impairment ratings, but most physicians have not received instruction about assessing impairment, disability, or causation and lack an adequate ability to assess these issues. Causation requires a given cause and a given effect that are associated with a reasonable degree of medical probability and also requires documentation with appropriate scientific evidence (not self-reports or historical time frames). Those who prepare and review assessments of impairment should ensure that clinical causation assessments were accurate, that the rating was performed at maximal medical improvement, that examination findings were consistent, and that the individual's normal state was determined.
  2. Impairment Tutorial: Rating Permanent Impairment for Artificial Disc Replacements

    James B. Talmage, Charles N. Brooks, Christopher R. Brigham

    Pages 6–8

    DOI: 10.1001/amaguidesnewsletters.2006.MayJun02

    Abstract
    In 2005, the Food and Drug Administration (FDA) approved an artificial disc replacement (ADR), and physicians likely will be called on to evaluate permanent impairment in some patients who have been treated using an ADR. The AMA Guides to the Evaluation of Permanent Impairment, (AMA Guides), Fifth Edition, was published in 2000, before the approval of ADRs, and thus is silent about evaluating ADR-associated impairment. FDA based its approval on the results of a study in which the indications were tightly limited and for which the list of relative contraindications was quite long. One review of 100 consecutive lumbar spine surgery patients found that 95% had at least 1 contraindication to ADR. The AMA Guides recommends using the Diagnosis-related estimates (DRE) method, but some situations (eg, multilevel involvement in the same spinal region) warrant use of the range-of-motion (ROM) method. Assuming a single injury and one level of loss of the activities of daily living, the DRE is the correct method to rate the permanent impairment, and the authors recommend that ADR be accepted as the equivalent to loss of motion segment integrity, warranting a rating from CRE Category IV. ADR is in its infancy, and until the AMA Guides, Sixth Edition, is available, evaluators can rate one level ADR from DRE Category IV.
AMA Newsletter

Newsletter information

ISSN
2642-0880
Publisher
American Medical Association
Publication date
5/1/2006

© 2006 American Medical Association. All Rights Reserved.

AMA Guides Digital
Cedaron Medical

Products

  • AMA Guides® Digital Subscription
  • AMA Guides® Digital + Newsletter Archive
  • ImpairmentCare
  • Compare subscriptions

AMA Guides

  • Explore AMA Guides
  • AMA Guides Training Resources
  • Contact Us
  • Subscription Terms

Account

  • Overview
  • Organizations and seats
  • Orders

© 2026 Cedaron Medical Inc. All rights reserved.

AMA Guides® is a registered trademark of the American Medical Association. © 2026 American Medical Association. All Rights Reserved.

Privacy